z-logo
open-access-imgOpen Access
Usefulness of intraductal RFA in patients with malignant biliary obstruction
Author(s) -
Sung Yong Han,
Dong Uk Kim,
Dae Hwan Kang,
Dong Hoon Baek,
Tae Hoon Lee,
Jae Hee Cho
Publication year - 2020
Publication title -
medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 148
eISSN - 1536-5964
pISSN - 0025-7974
DOI - 10.1097/md.0000000000021724
Subject(s) - medicine , radiofrequency ablation , radiology , stent , retrospective cohort study , interquartile range , bile duct , cohort , adverse effect , prospective cohort study , surgery , ablation
Background/Aims: Intraductal radiofrequency ablation (ID-RFA) is a novel therapy for unresectable malignant biliary obstructions. ID-RFA for perihilar lesions is associated with a high risk of adverse events. We aimed to evaluate the feasibility and efficacy of temperature-controlled ID-RFA for perihilar malignant biliary obstruction. Methods: Sixteen patients with pathologically proven perihilar cholangiocarcinoma were prospectively enrolled to evaluate the feasibility of hilar ID-RFA. Clinical efficacy and outcomes were subsequently evaluated in a multicenter retrospective cohort. Results: Nine of the 16 patients in the prospective cohort had Bismuth type IV and 7 had type IIIA perihilar cholangiocarcinoma. The median length of stricture was 34.5 mm. The median number of ID-RFA sessions was three, and all sessions were technically and functionally successful without severe adverse events. Clinical outcomes were assessed using a multicenter hilar ID-RFA cohort of 21 patients; the median stent patency and overall survival were 90 days (range: 35–483 days) and 147 days (range: 92–487 days), respectively. An approximate 16-month patency of the bile duct was maintained in one patient who had an intraductal growth pattern. In a comparison of the self-expandable metallic stent (SEMS) and plastic stent (PS) after hilar ID-RFA, no differences in stent patency (89 vs 90.5 days, respectively; P  = .912) and adverse events (20.0% vs 10%, respectively; P  = .739) were observed. Conclusions: ID-RFA at 7 W for 120 seconds is safe and feasible in patients with advanced perihilar cholangiocarcinoma. After ID-RFA, SEMS and PS placement showed comparable patency and survival rates. Trial registration number: KCT0003223

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here